| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
SCD1/5-IN-1 targets stearoyl-CoA desaturase 1 (SCD1) and stearoyl-CoA desaturase 5 (SCD5). SCD1 is a key enzyme in lipid metabolism that converts saturated fatty acids into monounsaturated fatty acids, playing a role in metabolic diseases and cancer. SCD5 is primarily expressed in the brain and is involved in neurodevelopment and neurological function. Inhibition of these enzymes modulates lipid composition and signaling pathways.
|
|---|---|
| ln Vitro |
In vitro, SCD1/5-IN-1 acts as a selective inhibitor of SCD1 and SCD5. The compound's inhibitory activity can be measured using enzyme activity assays that quantify the conversion of saturated fatty acids to monounsaturated fatty acids. Detailed in vitro potency data (IC₅₀ values) are not publicly available. The compound is used as a chemical tool to study the role of SCD1 and SCD5 in cellular processes.
|
| ln Vivo |
In vivo, SCD1/5-IN-1 is utilized in the research of neurological diseases. By inhibiting SCD1 and SCD5, the compound may modulate lipid metabolism in the brain, affecting neuroinflammation, neuronal function, and disease progression. Detailed in vivo efficacy data are limited. The compound is intended for research use only and is not for human therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for SCD1/5-IN-1 involve measuring the activity of SCD1 or SCD5 enzymes in a cell-free system. The assay typically uses a radiolabeled or fluorescent substrate (e.g., stearoyl-CoA) and measures the production of the desaturated product (oleoyl-CoA). The compound is added at various concentrations, and the inhibition of enzyme activity is calculated. IC₅₀ values are determined from dose-response curves.
|
| Cell Assay |
In vitro cellular assays for SCD1/5-IN-1 are conducted in cell lines expressing SCD1 or SCD5, such as neuronal or liver cells. Cells are treated with various concentrations of the compound for 24–72 hours. The fatty acid composition of cellular lipids is analyzed by gas chromatography-mass spectrometry (GC-MS) to measure the ratio of monounsaturated to saturated fatty acids. Cell viability and proliferation are assessed using standard assays.
|
| Animal Protocol |
In vivo animal studies for SCD1/5-IN-1 would be conducted in rodent models of neurological diseases. The compound would be administered orally or via intraperitoneal injection. Efficacy endpoints would include behavioral tests, histopathological analysis of brain tissue, and measurement of fatty acid composition in the brain. Detailed protocols are not publicly available, as this is a research compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for SCD1/5-IN-1 are limited. As a small molecule with a molecular weight of 258.24, the compound is expected to have reasonable oral bioavailability. Standard pharmacokinetic studies would involve administration to rodents with plasma concentration measured by LC-MS/MS. The compound is soluble in DMSO and can be formulated for in vivo administration.
|
| Toxicity/Toxicokinetics |
Preclinical toxicology data for SCD1/5-IN-1 are limited. As an investigational compound, its safety profile has not been fully established. The compound is for research use only and is not intended for human therapeutic use. Standard safety precautions for handling chemical inhibitors apply, including the use of appropriate personal protective equipment.
|
| References | |
| Additional Infomation |
SCD1/5-IN-1 (Compound 10) is a selective dual inhibitor of stearoyl-CoA desaturase 1 (SCD1) and stearoyl-CoA desaturase 5 (SCD5). It is utilized in the research of neurological diseases. The compound has a CAS number of 1241494-17-6 and a molecular formula of C₁₂H₁₀N₄O₃. This product is for research use only and is not intended for human therapeutic use.
|
| Molecular Formula |
C12H10N4O3
|
|---|---|
| Molecular Weight |
258.232801914215
|
| Exact Mass |
258.075
|
| CAS # |
1241494-17-6
|
| PubChem CID |
32608144
|
| Appearance |
Light yellow to brown solid powder
|
| LogP |
0.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
19
|
| Complexity |
341
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=C(C=N1)NC(=O)C2=NOC(=C2)C3=CC=CO3
|
| InChi Key |
FCICSKVGJNZDGZ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10N4O3/c1-16-7-8(6-13-16)14-12(17)9-5-11(19-15-9)10-3-2-4-18-10/h2-7H,1H3,(H,14,17)
|
| Chemical Name |
5-(furan-2-yl)-N-(1-methylpyrazol-4-yl)-1,2-oxazole-3-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~193.63 mM; with sonication)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.8725 mL | 19.3626 mL | 38.7252 mL | |
| 5 mM | 0.7745 mL | 3.8725 mL | 7.7450 mL | |
| 10 mM | 0.3873 mL | 1.9363 mL | 3.8725 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
